

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 6-K**

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

December 21, 2015

**uniQure N.V.**

**Matthew Kapusta, Chief Financial Officer  
Meibergdreef 61**

**Amsterdam 1105 BA, the Netherlands; Tel: +31-20-240-6000**  
(Address, Including ZIP Code, and Telephone Number,  
Including Area Code, of Registrant's Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-Fx Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

---

Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of uniQure N.V. (the "Company"), dated December 18, 2015, announcing the appointment of Daniel Soland as Chief Executive Officer of the Company.

Pursuant to his employment agreement, Mr. Soland's annual base salary will be \$500,000. He will be eligible to receive a discretionary annual bonus of up to 50% of his base salary, based on performance. In addition, he will receive an option to purchase 800,000 ordinary shares of the Company at a purchase price equal to the closing price on the Nasdaq Global Market on December 18, 2015, which was \$16.00 per share. Such option will vest over a four-year period, with one-quarter vesting on the first anniversary of the grant and the remainder vesting on a quarterly basis during the following three years.

Mr. Soland's appointment to the Board of the Company and his equity award will be presented to the shareholders of the Company for approval at an Extraordinary General Meeting of Shareholders to be convened in the first quarter of 2016.

2

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**UNIQUE N.V.**

Date: December 21, 2015

By: /S/ MATTHEW KAPUSTA  
Matthew Kapusta  
Chief Financial Officer

3

---

**INDEX TO EXHIBITS**

<u>Number</u>	<u>Description</u>
99.1	Press release of uniQure N.V., dated December 18, 2015, announcing the appointment of Daniel Soland as Chief Executive Officer of the Company





**FOR IMMEDIATE RELEASE**

**uniQure Appoints Dan Soland as Chief Executive Officer**

**Amsterdam, the Netherlands, December 18, 2015** — uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the appointment of Dan Soland as the new Chief Executive Officer of the Company. Mr. Soland will succeed Jörn Aldag, who has decided to step down as CEO, a role he has held since 2009. Mr. Soland will also be nominated for appointment to uniQure’s Management Board, subject to approval by the Company’s General Meeting of Shareholders. Mr. Aldag will be available to assist the Company during the transition.

Mr. Soland, 57, brings to uniQure more than 30 years of industry experience, most recently serving as Vice President and Chief Operating Officer of ViroPharma. At ViroPharma, Mr. Soland was responsible for building the company’s organization and commercial infrastructure until its successful sale to Shire in 2014 for approximately \$4 billion. Mr. Soland was previously President of Chiron Vaccines, where he helped engineer a turnaround that contributed to Chiron’s acquisition by Novartis. Earlier, he was President and CEO of Epigenesis Pharmaceuticals and Vice President and Director of Worldwide Marketing Operations at GlaxoSmithKline Biologicals and held positions of increasing responsibility at Pasteur-Merieux’s Connaught Laboratories (now Sanofi Pasteur). Mr. Soland holds a B.S. in Pharmacy from the University of Iowa.

“Dan’s appointment comes at an important time in the evolution and growth of uniQure,” commented Will Lewis, Chairman of uniQure’s Nomination and Governance Committee who led the search on behalf of the Supervisory Board. “He brings significant operational experience and knowledge of drug development that will be critical as uniQure’s pipeline advances into later-stage clinical studies. I am confident that Dan’s track record of generating shareholder value will enable uniQure to achieve the potential that we all believe is inherent in uniQure’s broad pipeline and leading gene therapy technology platform.”

“The Supervisory Board thanks Jörn for the leadership, energy and commitment that he has brought to uniQure since 2009. Without his significant contributions and leadership, uniQure would not have achieved its successes over the past six years,” continued Mr. Lewis.

“uniQure presents an exciting opportunity and I very much look forward to collaborating with the team on both sides of the Atlantic to advance our innovative portfolio of gene therapy candidates to patients,” commented Mr. Soland.

**About uniQure**

uniQure is delivering on the promise of gene therapy — single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. [www.uniQure.com](http://www.uniQure.com).

**uniQure:**

Matthew Kapusta  
Chief Financial Officer  
Direct: +1 339 970-7005  
[m.kapusta@uniquire.com](mailto:m.kapusta@uniquire.com)

**Media inquiries:**

Gretchen Schweitzer  
MacDougall Biomedical Communications  
Direct: +49 172 861 8540  
Main: +49 89 2424 3494 or +1 781 235 3060  
[gschweitzer@macbiocom.com](mailto:gschweitzer@macbiocom.com)

---